parkinsons-study-group

Overview

The Parkinson’s Study Group (PSG) is a non-profit, peer-reviewed research consortium dedicated to conducting clinical trials to advance treatments for Parkinson’s disease and related neurodegenerative disorders. Founded in 1985 as a network of academic medical centers across North America, the PSG has been instrumental in the development of nearly every FDA-approved Parkinson’s disease medication over the past four decades^{1The Parkinson's Study Group: a 30-year history2013 · Mov Disord · PMID 23483720Open reference2Parkinson's Study Group Official WebsiteOpen reference}.

As the premier clinical research network in the Parkinson’s field, the PSG has conducted landmark trials that have shaped standard of care, from levodopa formulations to dopamine agonists, MAO-B inhibitors, and disease-modifying therapies. The group’s multi-center, collaborative approach has enabled large-scale trials that would be impossible for individual institutions to conduct independently.

Mission and Objectives

The PSG’s mission is to advance the understanding and treatment of Parkinson’s disease and related disorders through:

• Clinical Excellence: Conducting high-quality, rigorous clinical trials following GCP guidelines

• Scientific Innovation: Investigating novel therapeutic approaches including neuroprotective and disease-modifying therapies

• Knowledge Generation: Advancing understanding of Parkinson’s disease through rigorous clinical research

• Training: Developing the next generation of clinical researchers in movement disorders

• Collaboration: Fostering partnerships with other research consortia, patient organizations, and industry

Research Focus Areas

The PSG conducts trials across multiple therapeutic domains^{3Parkinson disease: current issues in treatment1994 · J Neurol Neurosurg Psychiatry · PMID 8068096Open reference4New approaches to neuroprotection in Parkinson disease2009 · Neurology · PMID 19353659Open reference}:

Symptomatic Treatments

Dopaminergic Therapies

• Levodopa formulations: Optimization of carbidopa/levodopa combinations, extended-release formulations

• Dopamine agonists: Pramipexole, ropinirole, rotigotine, cabergoline

• MAO-B inhibitors: Rasagiline, selegiline, safinamide

• COMT inhibitors: Entacapone, tolcapone, opicapone

Motor Complications

The PSG has conducted extensive research on managing:

• Motor fluctuations: “Wear-off” phenomenon, delayed “on,” unpredictable “off” states

• Dyskinesias: Peak-dose dyskinesias, diphasic dyskinesias, off-period dystonia

• Treatment optimization: Continuous dopaminergic delivery, deep brain stimulation timing^{5Motor response complications and the treatment of Parkinson disease2001 · Neurology · PMID 11459935Open reference6Continuous dopaminergic stimulation in Parkinson disease2005 · Neurology · PMID 15668415Open reference}

Non-Motor Symptoms

Research encompasses the full spectrum of non-motor features:

• Sleep disorders: REM sleep behavior disorder, insomnia, excessive daytime sleepiness

• Cognitive impairment: Executive dysfunction, dementia, visual-spatial deficits

• Autonomic dysfunction: Orthostatic hypotension, constipation, urinary dysfunction

• Psychiatric features: Depression, anxiety, psychosis, apathy^{7Non-motor symptoms in Parkinson disease2013 · Curr Opin Neurol · PMID 23916965Open reference8Mood disorders in Parkinson disease2013 · Prog Neuropsychopharmacol Biol Psychiatry · PMID 23454227Open reference}

Disease-Modifying Therapies

The PSG has been at the forefront of disease-modifying therapy development:

Neuroprotective Agents

• Rasagiline: The ADAGIO trial demonstrated disease-modifying potential in early PD^{9A double-blind, delayed-start trial of rasagiline in Parkinson disease2009 · N Engl J Med · PMID 19387016Open reference}

• Pramipexole: The PROUD trial investigated disease-modifying effects

• Coenzyme Q10: Investigated in the QE3 trial for neuroprotection

Alpha-Synuclein-Targeted Therapies

• Immunotherapies targeting aggregated alpha-synuclein

• Small molecules inhibiting alpha-synuclein aggregation

• Gene therapy approaches targeting synuclein expression

LRRK2-Targeted Therapies

The PSG has played a critical role in LRRK2 inhibitor development:

• DNL151 (Denali) and other LRRK2 kinase inhibitors

• Genetic studies identifying LRRK2 mutation carriers for targeted trials

• Biomarker development for LRRK2-associated PD

GBA-Targeted Therapies

As the most common genetic risk factor for PD:

• GBA mutation carrier identification and characterization

• Modulator therapies targeting glucocerebrosidase

• Enhanced understanding of GBA-PD phenotype^{10Issues in neuroprotection trials in Parkinson disease2006 · Neurology · PMID 16567653Open reference}

Novel Therapeutic Approaches

Gene Therapy

• AAV-based delivery of GAD ( glutamic acid decarboxylase)

• AADC (amino acid decarboxylase) gene therapy

• TH (tyrosine hydroxylase) and GCH1 for dopamine synthesis

Cell Replacement Therapy

• Stem cell-derived dopamine neuron transplantation

• Research into optimal cell sources and delivery methods

Deep Brain Stimulation Optimization

• Target selection (STN vs. GPi)

• Stimulation parameter optimization

• Adaptive deep brain stimulation approaches

Immunotherapies

• Active vaccination against alpha-synuclein

• Passive antibody therapies

• Anti-inflammatory immunomodulation

Clinical Trial Network

The PSG comprises over 50 academic medical centers across North America, representing the largest coordinated clinical research network in movement disorders^{2Parkinson's Study Group Official WebsiteOpen reference}0:

Founding and Headquarters

• University of Rochester (Rochester, NY) has served as the PSG headquarters since its founding

• The data coordination center manages trial operations, data management, and statistical analysis

Member Institutions

The network includes leading movement disorder centers:

Northeast Region

• Columbia University (New York, NY)

• University of Pennsylvania (Philadelphia, PA)

• Johns Hopkins University (Baltimore, MD)

• Cornell University (New York, NY)

• Beth Israel Deaconess Medical Center (Boston, MA)

Southeast Region

• Emory University (Atlanta, GA)

• University of Florida (Gainesville, FL)

• Medical University of South Carolina (Charleston, SC)

Midwest Region

• University of Michigan (Ann Arbor, MI)

• Rush University (Chicago, IL)

• Washington University (St. Louis, MO)

• Cleveland Clinic (Cleveland, OH)

Southwest Region

• Baylor College of Medicine (Houston, TX)

• University of Texas Southwestern (Dallas, TX)

• University of Arizona (Phoenix, AZ)

West Coast

• University of Washington (Seattle, WA)

• Stanford University (Stanford, CA)

• University of California San Diego (San Diego, CA)

• Oregon Health and Science University (Portland, OR)

International Partnerships

The PSG collaborates internationally with:

• Parkinson’s UK Discovery Club

• International Parkinson’s Disease Genomics Consortium (IPDGC)

• Movement Disorder Society

• World Parkinson Congress

Landmark Clinical Trials

The PSG has contributed to numerous pivotal clinical trials that shaped Parkinson’s disease treatment^{2Parkinson's Study Group Official WebsiteOpen reference}1^{2Parkinson's Study Group Official WebsiteOpen reference}2:

Early Disease Trials

ELLDOPA Trial

The “Earlier vs Later Levodopa Therapy in PD” trial established that initial levodopa therapy provided superior motor symptom control compared to delayed treatment, addressing concerns about levodopa toxicity.

CALM-PD Trial

The “Comparison of the Agonist Pramipexole versus Levodopa on Motor Complications in Parkinson’s Disease” trial demonstrated that initial pramipexole treatment reduced the risk of motor complications, establishing dopamine agonists as first-line therapy in younger patients^{2Parkinson's Study Group Official WebsiteOpen reference}3^{2Parkinson's Study Group Official WebsiteOpen reference}4.

Disease Modification Trials

ADAGIO Trial

The “Attenuation of Disease Progression with Azilect” trial was a landmark delayed-start design demonstrating that rasagiline provided disease modification in early PD^{2Parkinson's Study Group Official WebsiteOpen reference}5. This trial established the first evidence of disease modification in PD.

PROUD Trial

The “Pramipexole on Underlying Disease” trial investigated whether pramipexole had disease-modifying effects using a similar delayed-start design.

TEMPO Trial

Early studies with rasagiline established the dose-response relationship and safety profile.

Advanced Disease Trials

LEAPS Trial

The “Levodopa-Carbidopa-Intestinal Gel” trial demonstrated the efficacy of continuous intrajejunal levodopa infusion for advanced PD with motor fluctuations^{2Parkinson's Study Group Official WebsiteOpen reference}6.

DBS Trials

Pivotal trials evaluating deep brain stimulation versus best medical therapy established the surgical treatment for advanced PD.

Non-Motor Symptom Trials

• Trials for depression in PD (sertraline, venlafaxine)

• Cognitive dysfunction treatment studies

• Sleep disorder management protocols

Collaboration with Other Consortia

The PSG maintains extensive collaborative relationships^{2Parkinson's Study Group Official WebsiteOpen reference}7:

Patient Advocacy Organizations

• Michael J. Fox Foundation for Parkinson’s Research (MJFF)

• Parkinson’s Foundation

• Parkinson’s Action Network

Research Consortia

• International Parkinson’s Disease Genomics Consortium (IPDGC)

• Accelerating Medicines Partnership for Parkinson’s Disease (AMP-PD)

• Parkinson’s Progression Markers Initiative (PPMI)

• Genetic Epidemiology of Parkinson’s Disease (GEOPD)

Clinical Trial Networks

• Huntington’s Disease Society of America (HDSA)

• ALS Clinical Research Learning Institute

• Critical Path for Parkinson’s (CPP)

Leadership and Governance

The PSG is governed by a Steering Committee comprising leading movement disorder specialists who provide strategic direction and oversee trial operations^{2Parkinson's Study Group Official WebsiteOpen reference}8:

Historical Leadership

• Dr. Karl Kieburtz (University of Rochester) - Long-serving Principal Investigator, instrumental in PSG growth

• Dr. Ira Shoulson (University of Rochester) - Founder and first chairman

• Dr. Matthew Stern (University of Pennsylvania) - Past chairman, DBS research

• Dr. Ray Kelly (University of Rochester) - Executive director

Current Leadership

The Steering Committee includes representatives from major member institutions who rotate leadership responsibilities. Standing committees include:

• Scientific Review Committee: Evaluates trial concepts and protocols

• Data Safety Monitoring Board: Independent oversight of trial safety

• Publication Committee: Manages scientific output and dissemination

• Training Committee: Oversees fellow and junior investigator development

Industry Partnerships

PSG collaborates with pharmaceutical companies including:

• AbbVie (Abbott)

• Biogen

• Denali Therapeutics

• Hoffmann-La Roche

• Lundbeck

• Merck

• Novartis

• Pfizer

• Sunovion

• Takeda

• UCB Pharma

Training and Education

The PSG invests in developing the next generation of movement disorder researchers:

Fellowship Programs

• Clinical research fellowships in PD

• Sub-specialty training in movement disorders

• Clinical trial methodology training

Educational Initiatives

• Annual meeting with scientific sessions

• Protocol development workshops

• Statistical analysis training

• Regulatory affairs education

Mentorship

Experienced PSG investigators mentor junior faculty and fellows through:

• Protocol development guidance

• Grant writing support

• Career development counseling

• Publication assistance

Impact on Parkinson’s Disease Care

The PSG’s contributions have fundamentally shaped modern Parkinson’s disease treatment:

Therapeutic Advances

• Every FDA-approved PD medication since 1985 has involved PSG research

• Established standards for motor complication management

• Defined disease-modifying therapy development paradigms

Clinical Research Infrastructure

• Created infrastructure for multi-center PD clinical trials

• Established data standards and outcome measures

• Developed quality control processes for clinical research

Scientific Knowledge

• Generated hundreds of peer-reviewed publications

• Trained numerous clinical researchers

• Established collaborative research norms

Future Directions

The PSG continues to evolve its research agenda:

Emerging Priorities

• Biomarker-driven trials: Using biomarkers for patient stratification and outcome measurement

• Precision medicine: Targeting specific genetic subtypes (LRRK2, GBA, SNCA)

• Combination therapies: Multi-target approaches for complex disease

• Digital health: Wearable devices and remote monitoring

• Regenerative approaches: Cell and gene therapy advancement

Infrastructure Development

• Enhanced data sharing capabilities

• Expanded patient registry

• Integration with electronic health records

• Real-world evidence collection

Research Methodology Innovations

The PSG has pioneered several methodological innovations in Parkinson’s disease clinical research:

Delayed-Start Trial Design: The ADAGIO trial established the delayed-start design as the gold standard for disease-modifying therapy assessment in PD. This design allows differentiation between symptomatic effects and true disease modification by comparing early-start versus delayed-start treatment groups^{2Parkinson's Study Group Official WebsiteOpen reference}9.

Biomarker Integration: The PSG has led efforts to incorporate biomarkers into clinical trials:

• Neuroimaging biomarkers (DaTscan, MRI)

• Cerebrospinal fluid biomarkers (alpha-synuclein, tau, beta-amyloid)

• Genetic biomarkers for patient stratification

• Digital biomarkers from wearable devices

Outcome Measure Validation: PSG investigators have validated novel outcome measures including:

• MDS-UPDRS (Movement Disorder Society-Unified Parkinson’s Disease Rating Scale)

• Non-motor symptom scales

• Quality of life instruments

• Patient-reported outcomes

Funding and Financial Model

The PSG operates through a combination of funding sources:

Federal Funding

• National Institute of Neurological Disorders and Stroke (NINDS)

• National Institute on Aging (NIA)

• Department of Defense

• Patient-Centered Outcomes Research PCORI

Foundation Support

• Michael J. Fox Foundation

• Parkinson’s Foundation

• Additional nonprofit organizations

Industry Partnerships

• Pharmaceutical company trial sponsorship

• Biotech collaborations

• Device company partnerships

Revenue Generation

• Trial coordination fees

• Data management services

• Consultation fees

Quality Assurance and Regulatory Compliance

The PSG maintains rigorous quality standards:

GCP Compliance

• International Conference on Harmonization guidelines

• FDA regulations (21 CFR Part 312)

• EMA directves

• Health Canada requirements

Site Certification

• Standardized site qualification processes

• Regular site audits

• Training and certification requirements

Data Management

• Electronic data capture systems

• Centralized statistical analysis

• Independent data monitoring

Patient Engagement and Recruitment

The PSG prioritizes patient-centric research:

Patient Advisory Board

• Input on trial design

• Outcome measure selection

• Recruitment strategies

• Results dissemination

Recruitment Innovations

• Social media engagement

• Patient registry utilization

• Minority outreach programs

• International recruitment

Retention Strategies

• Travel support programs

• Flexible visit scheduling

• Long-term follow-up protocols

Global Health Impact

The PSG’s work extends beyond North America:

International Trial Expansion

• European site expansion

• Asian Pacific participation

• Latin American sites

• Global recruitment strategies

Health Equity Initiatives

• Minority enrollment goals

• Diversity in clinical trials

• Access to investigational therapies

• Community engagement

Global Standard Setting

• International guideline development

• WHO collaboration

• Policy advocacy

• Training programs worldwide

Challenges and Opportunities

The PSG faces several challenges while pursuing new opportunities:

Challenges

• Increasing trial costs

• Regulatory complexity

• Competition for patients

• Biomarker validation gaps

• Academic incentive alignment

Opportunities

• Precision medicine approaches

• Gene therapy advancements

• Digital health integration

• Biomarker development

• International collaboration

Historical Context and Evolution

The PSG has evolved significantly since its founding:

1985-1995: Foundation Years

• Initial network establishment

• First large-scale trials

• Training program development

1995-2005: Expansion Era

• Multi-center trial infrastructure

• Industry partnership growth

• International recognition

2005-2015: Innovation Period

• Disease modification trials

• Genetic subtyping research

• Biomarker integration

2015-Present: Precision Medicine Era

• LRRK2 and GBA-focused trials

• Alpha-synuclein immunotherapy

• Digital health integration

Contributions to Related Disorders

The PSG has expanded beyond idiopathic Parkinson’s disease:

Atypical Parkinsonian Syndromes

• Progressive supranuclear palsy

• Multiple system atrophy

• Corticobasal degeneration

• Dementia with Lewy bodies

Parkinsonism-Plus Syndromes

• Vascular parkinsonism

• Drug-induced parkinsonism

• Post-traumatic parkinsonism

Hereditary Disorders

• Huntington’s disease (collaborative)

• Spinocerebellar ataxias

• Essential tremor

Education and Training Impact

The PSG’s training programs have shaped the field:

Career Development

• Movement disorder specialists trained

• Clinical trial investigators

• Academic researchers

• Industry leaders

Knowledge Dissemination

• Annual scientific meetings

• Publication of protocols

• Educational webinars

• Guidelines development

Future Vision

Looking ahead, the PSG aims to:

1. Accelerate disease modification: Focus on neuroprotective and regenerative approaches

2. Enable precision medicine: Tailor treatments to genetic and biomarker profiles

3. Integrate technology: Leverage digital health for monitoring and outcomes

4. Expand access: Increase global trial participation and diversity

5. Improve outcomes: Develop better therapies for all Parkinson’s patients

See Also

• Parkinson’s Disease

• Parkinson’s Disease Clinical Trials

• Michael J. Fox Foundation

• LRRK2 Consortium

• GBA-PD Consortium

• Parkinson’s Foundation

• University of Rochester

• Alpha-Synuclein

• Dopamine

• Deep Brain Stimulation

External Links

• Parkinson’s Study Group Official Website

• ClinicalTrials.gov: Parkinson’s Disease Trials

• PubMed: Parkinson’s Study Group Publications